Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis

Kissei Pharmaceutical Co., Ltd.

Overview

The purpose of this study is to evaluate the efficacy, safety, and dose-response relationship of KLH-2109 compared to placebo in Japanese patients with endometriosis.

Study Type

INTERVENTIONAL

Conditions

Endometriosis

Interventions

KLH-2109DRUG

PlaceboDRUG

Leuprorelin acetateDRUG

Eligibility

Sex: FEMALEMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female patients with endometriosis Exclusion Criteria: * Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Locations (1)

Unnamed facility

Multiple Locations, Japan

Outcomes

Primary Outcomes

Change of average Numerical Rating Scale (NRS) score of pelvic pain

Time frame: 12 weeks

Secondary Outcomes

Incidences of adverse events

Time frame: 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.